Terri Febbraro1, Katina Robison2, Jennifer Scalia Wilbur2, Jessica Laprise2, Amy Bregar3, Vrishali Lopes4, Robert Legare2, Ashley Stuckey2. 1. Women and Infants, Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: Terri.Febbraro@uchospitals.edu. 2. Women and Infants, Warren Alpert Medical School of Brown University, Providence, RI, USA; Program in Women's Oncology, USA. 3. Women and Infants, Warren Alpert Medical School of Brown University, Providence, RI, USA. 4. Women and Infants, Warren Alpert Medical School of Brown University, Providence, RI, USA; Division of Research, USA.
Abstract
OBJECTIVE: Genetic predisposition is responsible for 5-10% of breast cancer, 10% of ovarian cancer and 2-5% of uterine cancer. The study objective was to compare genetic counseling and testing referral rates among women with breast cancer that met NCCN referral guidelines to the referral rates among women with gynecologic cancers and determine predictors of referral. METHODS: Utilizing an institutional tumor registry database, patients from an academic women's oncology program were identified who met a subset of NCCN guidelines for genetic referral between 2004 and 2010. Patients diagnosed with ovarian cancer, breast cancer ≤50years of age, or uterine cancer <50years of age were included. A retrospective electronic chart review was conducted to evaluate for a genetic referral and uptake of genetic testing. RESULTS: 820 women were included (216 uterine, 314 breast, and 290 ovarian cancer). The overall genetic referral rate was 21.7%. 34% of eligible breast cancer patients were referred compared to 13.4% of uterine cancer and 14.5% of ovarian cancer patients (p<0.0001). Younger age, breast cancer diagnosis, family history and earlier stage were all significant referral predictors. The odds of being referred increased with the number of affected family members. 70.8% of referred patients, consulted with genetics. Among those who consulted with genetics, 95.2% underwent testing. CONCLUSIONS: Although increasing, genetic counseling remains underutilized across cancer diagnosis. Women with breast cancer are more likely to be referred than women with gynecologic cancers. Younger age, earlier stage and positive family history appear to be predictive of referral for genetic evaluation.
OBJECTIVE: Genetic predisposition is responsible for 5-10% of breast cancer, 10% of ovarian cancer and 2-5% of uterine cancer. The study objective was to compare genetic counseling and testing referral rates among women with breast cancer that met NCCN referral guidelines to the referral rates among women with gynecologic cancers and determine predictors of referral. METHODS: Utilizing an institutional tumor registry database, patients from an academic women's oncology program were identified who met a subset of NCCN guidelines for genetic referral between 2004 and 2010. Patients diagnosed with ovarian cancer, breast cancer ≤50years of age, or uterine cancer <50years of age were included. A retrospective electronic chart review was conducted to evaluate for a genetic referral and uptake of genetic testing. RESULTS: 820 women were included (216 uterine, 314 breast, and 290 ovarian cancer). The overall genetic referral rate was 21.7%. 34% of eligible breast cancerpatients were referred compared to 13.4% of uterine cancer and 14.5% of ovarian cancerpatients (p<0.0001). Younger age, breast cancer diagnosis, family history and earlier stage were all significant referral predictors. The odds of being referred increased with the number of affected family members. 70.8% of referred patients, consulted with genetics. Among those who consulted with genetics, 95.2% underwent testing. CONCLUSIONS: Although increasing, genetic counseling remains underutilized across cancer diagnosis. Women with breast cancer are more likely to be referred than women with gynecologic cancers. Younger age, earlier stage and positive family history appear to be predictive of referral for genetic evaluation.
Authors: C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler Journal: Int J Gynecol Cancer Date: 2011-07 Impact factor: 3.437
Authors: Francisco J Dominguez; Julie L Jones; Katherina Zabicki; Barbara L Smith; Michele A Gadd; Michele Specht; Daniel B Kopans; Richard H Moore; James S Michaelson; Kevin S Hughes Journal: Cancer Date: 2005-11-01 Impact factor: 6.860
Authors: A M Burton-Chase; S R Hovick; S K Peterson; S K Marani; S W Vernon; C I Amos; M L Frazier; P M Lynch; E R Gritz Journal: Clin Genet Date: 2013-03 Impact factor: 4.438
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Jan J Koornstra; Marian Je Mourits; Rolf H Sijmons; Annemarie M Leliveld; Harry Hollema; Jan H Kleibeuker Journal: Lancet Oncol Date: 2009-04 Impact factor: 41.316
Authors: M Bruno; M Digennaro; S Tommasi; B Stea; T Danese; F Schittulli; A Paradiso Journal: Eur J Cancer Care (Engl) Date: 2009-11-13 Impact factor: 2.520
Authors: Erica M Bednar; Holly D Oakley; Charlotte C Sun; Catherine C Burke; Mark F Munsell; Shannon N Westin; Karen H Lu Journal: Gynecol Oncol Date: 2017-06-10 Impact factor: 5.482
Authors: Christopher P Childers; Kimberly K Childers; Melinda Maggard-Gibbons; James Macinko Journal: J Clin Oncol Date: 2017-08-18 Impact factor: 44.544
Authors: Margaret I Liang; Deanna H Wong; Christine S Walsh; Robin Farias-Eisner; Joshua G Cohen Journal: J Genet Couns Date: 2017-08-07 Impact factor: 2.537
Authors: Erica M Bednar; Charlotte C Sun; Bethsaida Camacho; John Terrell; Alyssa G Rieber; Lois M Ramondetta; Ralph S Freedman; Karen H Lu Journal: Gynecol Oncol Date: 2018-12-08 Impact factor: 5.482
Authors: J Brian Szender; Jasmine Kaur; Katherine Clayback; Mollie L Hutton; June Mikkelson; Kunle Odunsi; Cara Dresbold Journal: Int J Gynecol Cancer Date: 2018-01 Impact factor: 3.437
Authors: Christine Garcia; Kara Harrison; Kari L Ring; Mackenzie W Sullivan; Lisa A Rauh; Susan C Modesitt Journal: Fam Cancer Date: 2019-07 Impact factor: 2.375
Authors: Erica M Bednar; Michael T Walsh; Ellen Baker; Kimberly I Muse; Holly D Oakley; Rebekah C Krukenberg; Cara S Dresbold; Sandra B Jenkinson; Amanda L Eppolito; Kelly B Teed; Molly H Klein; Nichole A Morman; Elizabeth C Bowdish; Pauline Russ; Emaline E Wise; Julia N Cooper; Michael W Method; John W Henson; Andrew V Grainger; Banu K Arun; Karen H Lu Journal: J Genet Couns Date: 2018-05-16 Impact factor: 2.537